MEDBOT-B Shares Surge Over 6% Again on Surging Revenue Target

Stock News04-15

MEDBOT-B (02252) rose more than 6% again. At the time of writing, the stock was up 6.4%, trading at HK$32.24 with a turnover of HK$267 million. The surgical robotics sector has recently seen a series of positive developments, with continued policy support. Measures released by the Beijing Medical Insurance Bureau and other departments propose promoting the adoption of surgical robots in hospitals. Additionally, the Hunan Medical Insurance Bureau recently clarified the pricing standards for surgical robots and related auxiliary procedures. Industry experts believe surgical robots offer significant clinical benefits, and their global penetration rate is expected to keep rising. A UBS research report noted that the company's overseas revenue surged 287% year-over-year last year, with sales of its "Toumai" surgical robot increasing more than fivefold. The report indicated that MEDBOT-B aims to double its total revenue in 2026 compared to 2025 and expects the proportion of overseas revenue to rise from 73% last year to over 80%, potentially helping the company achieve breakeven in the first half of 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1114033135?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-15 14:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1114033135","market":"hk","top_or_hot":-1,"title":"MEDBOT-B Shares Surge Over 6% Again on Surging Revenue Target","media":"Stock News","content":"<p>MEDBOT-B (02252) rose more than 6% again. At the time of writing, the stock was up 6.4%, trading at HK$32.24 with a turnover of HK$267 million. The surgical robotics sector has recently seen a series of positive developments, with continued policy support. Measures released by the Beijing Medical Insurance Bureau and other departments propose promoting the adoption of surgical robots in hospitals. Additionally, the Hunan Medical Insurance Bureau recently clarified the pricing standards for surgical robots and related auxiliary procedures. Industry experts believe surgical robots offer significant clinical benefits, and their global penetration rate is expected to keep rising. A UBS research report noted that the company's overseas revenue surged 287% year-over-year last year, with sales of its \"Toumai\" surgical robot increasing more than fivefold. The report indicated that MEDBOT-B aims to double its total revenue in 2026 compared to 2025 and expects the proportion of overseas revenue to rise from 73% last year to over 80%, potentially helping the company achieve breakeven in the first half of 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MEDBOT-B Shares Surge Over 6% Again on Surging Revenue Target</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMEDBOT-B Shares Surge Over 6% Again on Surging Revenue Target\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-04-15 14:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>MEDBOT-B (02252) rose more than 6% again. At the time of writing, the stock was up 6.4%, trading at HK$32.24 with a turnover of HK$267 million. The surgical robotics sector has recently seen a series of positive developments, with continued policy support. Measures released by the Beijing Medical Insurance Bureau and other departments propose promoting the adoption of surgical robots in hospitals. Additionally, the Hunan Medical Insurance Bureau recently clarified the pricing standards for surgical robots and related auxiliary procedures. Industry experts believe surgical robots offer significant clinical benefits, and their global penetration rate is expected to keep rising. A UBS research report noted that the company's overseas revenue surged 287% year-over-year last year, with sales of its \"Toumai\" surgical robot increasing more than fivefold. The report indicated that MEDBOT-B aims to double its total revenue in 2026 compared to 2025 and expects the proportion of overseas revenue to rise from 73% last year to over 80%, potentially helping the company achieve breakeven in the first half of 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ROBO","symbol_name":"全球机器人自动化ETF-ROBO","start_time":0,"source_url":"","article_id":"1114033135","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1114033135","pubTimestamp":1776233431,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"MEDBOT-B (02252) rose more than 6% again. At the time of writing, the stock was up 6.4%, trading at HK$32.24 with a turnover of HK$267 million. The surgical robotics sector has recently seen a series...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ROBO":"全球机器人自动化ETF-ROBO","BK1617":"AI医疗","02252":"微创机器人-B","BK1100":"医疗保健设备","BK4588":"碎股","BK4585":"ETF&股票定投概念","VXUS":"国际股票ETF-Vanguard"},"translate_title":"由于收入目标飙升，MEDBOT-B股价再次飙升超过6%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VXUS":1,"02252":1,"ROBO":1},"content_text":"MEDBOT-B (02252) rose more than 6% again. At the time of writing, the stock was up 6.4%, trading at HK$32.24 with a turnover of HK$267 million. The surgical robotics sector has recently seen a series of positive developments, with continued policy support. Measures released by the Beijing Medical Insurance Bureau and other departments propose promoting the adoption of surgical robots in hospitals. Additionally, the Hunan Medical Insurance Bureau recently clarified the pricing standards for surgical robots and related auxiliary procedures. Industry experts believe surgical robots offer significant clinical benefits, and their global penetration rate is expected to keep rising. A UBS research report noted that the company's overseas revenue surged 287% year-over-year last year, with sales of its \"Toumai\" surgical robot increasing more than fivefold. The report indicated that MEDBOT-B aims to double its total revenue in 2026 compared to 2025 and expects the proportion of overseas revenue to rise from 73% last year to over 80%, potentially helping the company achieve breakeven in the first half of 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1114033135","isCrawlerRequest":true}